Mucosal adjuvant

Abstract

A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.

Claims

1. A mucosal vaccine composition, comprising: a mucosal adjuvant comprising tetragalloyl-D-lysine dendrimer (TGDK); and an immunogen, which is an antigen of influenza virus, wherein the TGDK is not chemically bound to the immunogen and present in a free molecular state in the mucosal vaccine composition.

2. The mucosal vaccine composition of claim 1, further comprising: a pharmaceutically acceptable carrier.

3. The mucosal vaccine composition of claim 1, wherein the immunogen is a whole particle or a split antigen of influenza virus.

4. A mucosal vaccine composition, comprising: an inactivated viral mucosal adjuvant comprising tetragalloyl-D-lysine dendrimer (TGDK); and an immunogen, wherein the immunogen is a whole particle or a split antigen of influenza virus.

5. A method for preparing the mucosal vaccine composition of claim 1, the method comprising: mixing the TGDK with the immunogen.

6. A mucosal vaccine therapy, comprising: administering an effective amount of the mucosal vaccine composition of claim 1 to a subject in need thereof.

7. The mucosal vaccine composition of claim 1, wherein the TGDK is included in an amount of 0.03 to 30 μg/10 μL.

8. The mucosal vaccine composition of claim 1, wherein the TGDK is included in an amount of 0.03 to 0.3 μg/10 μL.

Description

BRIEF DESCRIPTION OF DRAWINGS

(1) FIG. 1 shows the A/California/07/2009 strain-specific IgG antibody titer of a split antigen administration group.

(2) FIG. 2 shows the B/Texas/2/2013 strain-specific IgG antibody titer of a split antigen administration group.

(3) FIG. 3 shows the A/California/07/2009 strain-specific IgG antibody titer of an inactivated whole-virus antigen administration group.

(4) FIG. 4 shows the B/Texas/2/2013 strain-specific IgG antibody titer of an inactivated whole-virus antigen administration group.

(5) FIG. 5 shows the geometric mean values of B/Texas/2/2013 strain-specific IgG1 and IgG2a antibody titers in each group.

(6) FIG. 6 shows the A/California/07/2009 strain-specific IgG antibody titer.

(7) FIG. 7 shows the B/Texas/2/2013 strain-specific IgG antibody titer.

DESCRIPTION OF EMBODIMENTS

(8) In the present invention, the term “TGDK” is an abbreviation of tetragalloyl-D-lysine dendrimer and refers to N2,N6-bis[N2,N6-bis(3,4,5-trihydroxybenzoyl)-lysyl]-N-(2-aminoethyl)-lysinamide. TGDK is known as a target molecule of M cells, antigen sampling cells present in the mucosa.

(9) TGDK can be produced, for example, by use of a tetragalloyl-D-trilysinyl diethylamine solid-phase method using gallic acid and D-lysine (see Non Patent Literature 4 described above).

(10) As shown in Examples described later, in the case of mucosally administering a vaccine composition prepared by mixing an influenza vaccine strain (a split antigen/an inactivated whole-virus antigen) with TGDK to mice, the titer of induced IgG specifically binding to the antigen is significantly higher than that for a TGDK non-addition group. In the case of inducing immunity with the split antigen added with TGDK, an IgG titer is obtained at substantially the same level as in the case of inducing immunity using the inactivated whole-virus antigen alone. As for the geometric mean titers (GMT) of IgG1 and IgG2a, GMT is markedly elevated in IgG2a excellent in the ability to defend against infection with influenza virus.

(11) Specifically, TGDK has mucosal adjuvant activity of enhancing the antibody-inducing ability in case of the mucosal administration of an immunogen (antigen). Accordingly, TGDK can serve as a mucosal adjuvant. A composition containing TGDK and a pharmaceutically acceptable carrier can serve as a mucosal adjuvant composition. TGDK can also be used for producing a mucosal adjuvant or a mucosal adjuvant composition.

(12) In the present invention, the term “mucosal adjuvant” means a substance increasing immune response to an immunogen when the immunogen is mucosally administered.

(13) In this context, the term “mucosal administration” refers to an administration mode via the mucosa. The “mucosa” refers to an internal wall of, particularly, a hollow organ which communicates with the outside, such as the digestive organ, the respiratory organ, the urogenital organ, or the eye, in vertebrates. Thus, examples of such mucosal administration include, but are not limited to, nasal administration (transnasal administration), oral administration, intravaginal administration, upper airway administration, alveolar administration, and eye drop administration.

(14) The mucosal adjuvant or the mucosal adjuvant composition of the present invention can be mucosally administered in combination with an immunogen. The administration may be performed concurrently with administration of the immunogen or may be performed before or after administration of the immunogen.

(15) The dose of the mucosal adjuvant or the mucosal adjuvant composition of the present invention can be appropriately determined according to a subject, an administration method, an administration mode, and the type of an antigen substance.

(16) The mucosal adjuvant of the present invention can be provided as a mucosal vaccine composition in combination with an immunogen. The mucosal vaccine composition of the present invention can be prepared by mixing an immunogen with TGDK, and further can be provided as an appropriate preparation by appropriately adding a pharmaceutically acceptable carrier. In the mucosal vaccine composition of the present invention, TGDK is not in a state chemically bound to the immunogen or other components and is present in a free molecular state.

(17) Examples of the “immunogen” (antigen) include a pathogen of transmucosal infection (e.g., viruses and pathogenic bacteria) and a natural product purified from the pathogen, and a protein, peptide, and polysaccharide artificially prepared by approaches such as gene recombination, specifically, a virion which is a complete virus particle, incomplete virus particles, virion-constituting particle, virus non-structural protein, pathogenic bacteria-derived protein and glycoprotein, protective antigen, and epitope for neutralization reaction. The immunogen includes both one having infectivity and one lacking infectivity (inactivated antigen). Examples of the inactivated antigen include, but are not limited to, an antigen inactivated by physical (e.g., X ray irradiation, heat, and ultrasound) or chemical (formalin, mercury, alcohols, chlorine) operation. The immunogen derived from the pathogen of transmucosal infection is desirably an inactivated antigen derived from the virus or the pathogenic bacteria described above from the viewpoint of safety.

(18) Examples of the virus include chickenpox virus, measles virus, mumps virus, poliovirus, rotavirus, influenza virus, adenovirus, herpesvirus, severe acute respiratory syndrome (SARS) virus, human immunodeficiency virus (HIV), human papillomavirus, and rubella virus. The virus is preferably influenza virus or human immunodeficiency virus, more preferably influenza virus. A whole particle virus may be used as the influenza virus. In the present invention, a split antigen can be used, which is obtained by disrupting virus particles and removing lipids in envelopes.

(19) Examples of the pathogenic bacteria include Bordetella pertussis, Neisseria meningitidis, Haemophilus influenzae type b, pneumococcal bacteria, Mycobacterium tuberculosis, Vibrio cholerae, and Corynebacterium diphtheriae.

(20) Examples of the dosage form of the mucosal vaccine composition include a solution, suspension, and powder.

(21) Examples of the solution include an agent dissolved in purified water, a buffer solution or the like. Examples of the suspension include an agent suspended in purified water, a buffer solution or the like, together with methylcellulose, hydroxymethylcellulose, polyvinylpyrrolidone, gelatin, casein, or the like. Examples of the powder include an agent well mixed with methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, or the like.

(22) These preparations can be supplemented, if necessary, with an absorption promoter, a surfactant, a preservative, a stabilizer, a moisture proofing agent, a moisturizing agent, a solubilizer, etc. usually used.

(23) The mucosal vaccine composition of the present invention may contain an adjuvant other than TGDK as long as it does not impair the immunogenicity and safety of the vaccine.

(24) The amount of the immunogen contained in the mucosal vaccine composition of the present invention is not particularly limited as long as the amount is sufficient for producing antigen-specific IgG. The amount can be appropriately set in consideration of a ratio to TGDK used in combination therewith. For example, in the case of using a split antigen of influenza virus as the antigen, the split antigen may be contained in a range from 1 to 60 μg of HA (based on HA) more preferably from 9 to 15 μg of HA (based on HA), which is a single dose. The concentration is a value obtained by measuring the concentration of the HA protein through a testing method stipulated by WHO or national standards, such as a single radial immunodiffusion testing method or an HA content method.

(25) The content of TGDK in the mucosal vaccine composition may be appropriately adjusted in consideration of an antibody titer. TGDK may be contained in a range, for example, from 0.03 to 30 μg, more preferably from 0.03 to 0.3 μg, which is a single dose.

(26) The administration route of the vaccine composition of the present invention is not particularly limited. Oral administration or parenteral administration (e.g., nasal administration and eye drop administration) may be used. The vaccine composition of the present invention is administered by, for example, dropping, nebulizing or spraying into the nasal cavity or the oral cavity.

(27) Examples of the subject of the adjuvant composition or the vaccine composition of the present invention include humans and non-human mammals. A human is preferred. Examples of the non-human mammal include mice, rats, hamsters, guinea pigs, rabbits, pigs, cattle, goats, horses, sheep, dogs, cats, monkeys, orangutans, and chimpanzees.

EXAMPLES

(28) Hereinafter, the present invention will be described in more detail with reference to Examples. However, the present invention is not limited by these examples.

Example 1

(29) (1) Each stock solution of influenza HA vaccine “SEIKEN” A/H1N1 subtype (A/California/07/2009 strain) and B/Yamagata lineage (B/Texas/2/2013 strain) was used as a split antigen. These split antigens were mixed and combined such that the amount of hemagglutinin of each strain was 1 μg per 10 μL. TGDK was added thereto to have a final concentration of 0.03 to 30 μg/10 μL. For controls, an adjuvant-non-added dosing solution and a dosing solution added with gallic acid (control of TGDK) to have 30 μg/10 μL were also prepared (Table 1) because TGDK is a substance composed of 4 molecules of gallic acid bound to primary amine of a skeleton formed by 3 molecules of lysine. As in the split antigens, inactivated whole-virus antigens of A/H1N1 subtype (A/California/07/2009 strain) and B/Yamagata lineage (B/Texas/2/2013 strain) were mixed and combined such that the amount of hemagglutinin of each strain was 1 μg per 10 μL. Each dosing solution of the inactivated whole-virus antigens was prepared so as to contain 0.03 or 0.3 μg of TGDK or 30 μg of gallic acid (Table 1).

(30) The preparation of the inactivated whole-virus antigens used in this Example is as described below. The virus was inoculated into the chorioallantoic cavity of a 12 day-old embryonated chicken egg and cultured for 2 days. Then, chorioallantoic fluid was collected. The collected chorio-allantoic fluid was clarified by filter filtration and then adsorbed on barium sulfate, and eluted with 12% sodium citrate solution to collect influenza virus. The solution of collected virus was replaced with 6.7 mM phosphate-buffered saline (pH 7.2) by ultrafiltration. After replacement of buffer, a fraction containing the influenza virus was collected by sucrose density gradient centrifugation to thereby complete purification. To this purified influenza virus, beta-propiolactone as an inactivating agent was added to have a final concentration of 0.05% followed by allowing the mixture to react at 4° C. for 24 hours to inactivate the infectivity of the influenza virus. After this inactivation reaction, the buffer was replaced with 6.7 mM phosphate-buffered saline containing 1 w/w % sucrose (pH 7.2) by ultrafiltration (MWCO: 100,000). The resultant was used as an inactivated whole-virus vaccine.

(31) (2) Each dosing solution (Table 1) prepared as described above was administered at a dose of 5 μL per nasal cavity (10 μL in total) to BALB/c mice (female, 5 week-old) (8 animals per group) twice at a 3 week-interval. Two weeks after the second administration, whole blood was collected. Blood serum was prepared by centrifugation. The titer of IgG (total IgG) specifically binding to the A/California/07/2009 strain and the B/Texas/2/2013 strain was measured in the serum. The respective titers of IgG subclass IgG1 and IgG2a were measured as B/Texas/2/2013 strain-specific antibody titers for the serum of an adjuvant non-addition group and a TGDK 0.3 μg addition group of the split antigens and the inactivated whole-virus antigens.

(32) TABLE-US-00001 TABLE 1 Antigen Dose Adjuvant Type/subtype Type of (μg HA/ Adjuvant Dose Administration # and lineage Strain antigen strain/shot) name (μg/Shot) route A A/H1N1 A/California/07/2009 Split 1 TGDK 30 Transnasal B/Victoria B/Texas/2/2013 B A/H1N1 A/California/07/2009 Split 1 TGDK  3 Transnasal B/Victoria B/Texas/2/2013 C A/H1N1 A/California/07/2009 Split 1 TGDK  0.3 Transnasal B/Victoria B/Texas/2/2013 D A/H1N1 A/California/07/2009 Split 1 TGDK  0.03 Transnasal B/Victoria B/Texas/2/2013 E A/H1N1 A/California/07/2009 Split 1 — — Transnasal B/Victoria B/Texas/2/2013 F A/H1N1 A/California/07/2009 Split 1 Gallic acid 30 Transnasal B/Victoria B/Texas/2/2013 G A/H1N1 A/California/07/2009 Whole 1 — — Transnasal B/Victoria B/Texas/2/2013 particles H A/H1N1 A/California/07/2009 Whole 1 TGDK  0.3 Transnasal B/Victoria B/Texas/2/2013 particles I A/H1N1 A/California/07/2009 Whole 1 TGDK  0.03 Transnasal B/Victoria B/Texas/2/2013 particles J A/H1N1 A/California/07/2009 Whole 1 Gallic acid 30 Transnasal B/Victoria B/Texas/2/2013 particles

(33) (3) The IgG titers of split antigen administration groups (A to F) and an adjuvant non-addition inactivated whole-virus antigen administration group (G) are as shown in FIGS. 1 and 2. The addition of 0.03 to 30 μg of TGDK per dose to the split antigens elevated an antigen-specific IgG titer in blood for both the strains, as compared with adjuvant non-addition. This IgG titer was at substantially the same level as in the inactivated whole-virus antigens. Particularly, the IgG titer for the A/California/07/2009 strain in the groups added with 0.03 to 0.3 μg of TGDK, and the IgG titer for the B/Texas/2/2013 strain in the groups added with 0.03 to 3 μg of TGDK were significantly higher as compared with those for adjuvant non-addition (Mann-Whitney U test, p<0.05). When gallic acid was added to the split antigens, the IgG titer for the A/California/07/2009 strain was at substantially the same level as in adjuvant non-addition, whereas the IgG titer for the B/Texas/2/2013 strain was significantly decreased as compared with adjuvant non-addition. Polyphenol reportedly has an antioxidative effect or an effect of stimulating immunity. In this Example, monomolecular gallic acid does not have adjuvant activity of enhancing antibody induction. This suggested that the structure of TGDK composed of 4 molecules of gallic acid bound to primary amine of a skeleton formed by 3 molecules of lysine is important for exerting adjuvant activity.

(34) FIGS. 3 and 4 show results of inactivated whole-virus antigen administration groups (H to J). It was found that as in the split antigens, the addition of 0.03 or 0.3 μg of TGDK per dose to the inactivated whole-virus antigens increased IgG titers for both the strains, whereas the addition of gallic acid provided an IgG titer for the A/California/07/2009 strain at substantially the same level as in the adjuvant non-addition group, and decreased an IgG titer for the B/Texas/2/2013 strain. Thus, results similar to those of the split antigens were obtained in the inactivated whole-virus antigens. However, the effect of increasing IgG titers by the addition of TGDK is smaller for the inactivated whole-virus antigens than for the split antigens. This is because the inactivated whole-virus antigens themselves have high immunogenicity. It was confirmed that TGDK can exert adjuvant activity in transnasal administration for both of two types of antigens (split antigen and inactivated whole particle antigen) different in immunogenicity.

(35) FIG. 5 shows the geometric mean titers (GMT) of IgG1 and IgG2a in each group. As seen therefrom, the addition of TGDK markedly elevated an IgG2a titer for both the split antigens and the inactivated whole-virus antigens. IgG2a which is induced by Th1 response is superior in the ability to defend against infection with influenza virus to IgG1 which is induced by Th2 response. Therefore, the addition of TGDK is expected to further increase efficacy.

Reference Example 1

(36) (1) TGDK was evaluated for its adjuvant activity in subcutaneous administration in the test groups of Table 2 using the same antigens as in Example 1. In this evaluation, Alum (manufactured by Thermo Fisher Scientific Inc., Imject Alum) was additionally used as a control, which is a proven adjuvant for subcutaneous administration.

(37) TABLE-US-00002 TABLE 2 Antigen Adjuvant Type/subtype Type of Dose (μg HA/ Adjuvant Dose Administration and lineage Strain antigen strain/shot) name (μg/Shot) route A/H1N1 A/California/07/2009 Split 1 TGDK 30 Subcutaneous B/Victoria B/Texas/2/2013 A/H1N1 A/California/07/2009 Split 1 TGDK  3 Subcutaneous B/Victoria B/Texas/2/2013 A/H1N1 A/California/07/2009 Split 1 TGDK  0.3 Subcutaneous B/Victoria B/Texas/2/2013 A/H1N1 A/California/07/2009 Split 1 TGDK  0.03 Subcutaneous B/Victoria B/Tcxas/2/2013 A/H1N1 A/California/07/2009 Split 1 — — Subcutaneous B/Victoria B/Texas/2/2013 A/H1N1 A/California/07/2009 Split 1 Alm 30 Subcutaneous B/Victoria B/Texas/2/2013 A/H1N1 A/California/07/2009 Whole 1 Gallic acid 30 Subcutaneous B/Victoria B/Tcxas/2/2013 particles A/H1N1 A/California/07/2009 Whole 1 — — Subcutaneous B/Victoria B/Texas/2/2013 particles

(38) (2) FIG. 6 shows an IgG titer for the A/California/07/2009 strain. FIG. 7 shows an IgG titer for the B/Texas/2/2013 strain. The IgG titers for both the strains in groups added with TGDK were at substantially the same level as in the single administration of the split antigens. Thus, no adjuvant activity was confirmed. Higher IgG titers were exhibited in Alum and inactivated whole-virus administration groups (WV) as compared with the single administration of the split antigens. In subcutaneous administration, the IgG titers for both the strains in a gallic acid addition group were at substantially the same level as in the split antigen single administration group. Neither the gallic acid derivative TGDK nor gallic acid had adjuvant activity in subcutaneous administration.